Academic Journal
Advances in Nanomedicine for Precision Insulin Delivery
| Title: | Advances in Nanomedicine for Precision Insulin Delivery |
|---|---|
| Authors: | Alfredo Caturano, Roberto Nilo, Davide Nilo, Vincenzo Russo, Erica Santonastaso, Raffaele Galiero, Luca Rinaldi, Marcellino Monda, Celestino Sardu, Raffaele Marfella, Ferdinando Carlo Sasso |
| Source: | Pharmaceuticals, Vol 17, Iss 7, p 945 (2024) |
| Publisher Information: | MDPI AG, 2024. |
| Publication Year: | 2024 |
| Collection: | LCC:Medicine LCC:Pharmacy and materia medica |
| Subject Terms: | nanomedicine, insulin, precision insulin delivery, next-generation nanocarriers, targeted drug delivery, Medicine, Pharmacy and materia medica, RS1-441 |
| More Details: | Diabetes mellitus, which comprises a group of metabolic disorders affecting carbohydrate metabolism, is characterized by improper glucose utilization and excessive production, leading to hyperglycemia. The global prevalence of diabetes is rising, with projections indicating it will affect 783.2 million people by 2045. Insulin treatment is crucial, especially for type 1 diabetes, due to the lack of β-cell function. Intensive insulin therapy, involving multiple daily injections or continuous subcutaneous insulin infusion, has proven effective in reducing microvascular complications but poses a higher risk of severe hypoglycemia. Recent advancements in insulin formulations and delivery methods, such as ultra-rapid-acting analogs and inhaled insulin, offer potential benefits in terms of reducing hypoglycemia and improving glycemic control. However, the traditional subcutaneous injection method has drawbacks, including patient compliance issues and associated complications. Nanomedicine presents innovative solutions to these challenges, offering promising avenues for overcoming current drug limitations, enhancing cellular uptake, and improving pharmacokinetics and pharmacodynamics. Various nanocarriers, including liposomes, chitosan, and PLGA, provide protection against enzymatic degradation, improving drug stability and controlled release. These nanocarriers offer unique advantages, ranging from enhanced bioavailability and sustained release to specific targeting capabilities. While oral insulin delivery is being explored for better patient adherence and cost-effectiveness, other nanomedicine-based methods also show promise in improving delivery efficiency and patient outcomes. Safety concerns, including potential toxicity and immunogenicity issues, must be addressed, with the FDA providing guidance for the safe development of nanotechnology-based products. Future directions in nanomedicine will focus on creating next-generation nanocarriers with precise targeting, real-time monitoring, and stimuli-responsive features to optimize diabetes treatment outcomes and patient safety. This review delves into the current state of nanomedicine for insulin delivery, examining various types of nanocarriers and their mechanisms of action, and discussing the challenges and future directions in developing safe and effective nanomedicine-based therapies for diabetes management. |
| Document Type: | article |
| File Description: | electronic resource |
| Language: | English |
| ISSN: | 17070945 1424-8247 |
| Relation: | https://www.mdpi.com/1424-8247/17/7/945; https://doaj.org/toc/1424-8247 |
| DOI: | 10.3390/ph17070945 |
| Access URL: | https://doaj.org/article/3520787af9154a5887c8891162ec911d |
| Accession Number: | edsdoj.3520787af9154a5887c8891162ec911d |
| Database: | Directory of Open Access Journals |
| Full text is not displayed to guests. | Login for full access. |
| ISSN: | 17070945 14248247 |
|---|---|
| DOI: | 10.3390/ph17070945 |
| Published in: | Pharmaceuticals |
| Language: | English |